SkinBioTherapeutics Plc (SBTX) is a Biotechnology company in the Healthcare sector, listed on London Exchange. This page provides the complete earnings calendar, dividend schedule, and financial data for SkinBioTherapeutics Plc in 2026. The next earnings report is expected on December 2, 2026.
Next earnings date
02 Dec 2026
In 103 days
EPS estimate
—
Revenue estimate
5.1M
Past earnings
No dividend history available.
SkinBioTherapeutics plc, a life science company, engages in the research and development of technology that harnesses the human microbiome to improve health. The company develops SkinBiotix technology that can enhance the barrier effect of skin models, protect skin from infections, and repair wounds; and AxisBiotix that focuses on the gut-skin relationship and is designed to alleviate the symptoms associated with psoriasis. It serves cosmetic skincare, food supplements, medical skin care, infection control, and pharmaceutical skincare markets. The company has a collaboration agreement with Croda Plc; the University of Manchester to develop immune-supporting microbiome formulations; and Winclove Probiotics B.V. for the development of a probiotic blend of good bacterial strains based on the modifying properties of specific bacterial species in known psoriasis pathways. The company was formerly known as Skinbiotix Ltd and changed its name to SkinBioTherapeutics plc in December 2016. SkinBioTherapeutics plc was incorporated in 2015 and is based in Newcastle upon Tyne, the United Kingdom.
SkinBioTherapeutics Plc (SBTX) is scheduled to report earnings on December 2, 2026.
SkinBioTherapeutics Plc (SBTX) last reported earnings on June 8, 2026.
SkinBioTherapeutics Plc (SBTX) is listed on London Exchange.
We use cookies to make our website work and improve your experience. With your consent, we also use cookies for analytics and advertising.